Retatrutide Regulatory Record: Federal Federal Compounding Status Record
At a glance
- Review question / What do current federal and registry sources establish about federal Federal Compounding Status Record?
- Best evidence / FDA, federal-regulation, and registry records
- Evidence snapshot / 2026-08-09
- Commercial status / no FDA-approved product or ordinary retail supply
- HealthRX.com role / independent educational review; no retatrutide product or treatment offer
Evidence map for federal Federal Compounding Status Record
| Primary source | What the record documents | What the record cannot establish alone |
|---|---|---|
| FDA status statement for unapproved GLP-1 drugs | Documents that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| FDA warning letter addressing compounded retatrutide | Explains why retatrutide products described as compounded did not qualify for the federal compounding exemptions discussed in the letter. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| 21 CFR 312.7, Promotion of investigational drugs | Separates scientific exchange from promotional representations of an investigational drug as safe or effective. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| ClinicalTrials.gov pre-approval expanded-access record NCT07629401 | A registry entry for eligibility-limited pre-approval expanded access. It is not commercial approval, retail availability, ordinary prescribing, or a HealthRX.com service. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
What remains unresolved
A completed trial, publication, patent, pipeline announcement, registry status, or expanded-access record does not itself change approval status or create ordinary commercial availability.
What evidence could change the answer
A change in status should be verified through an FDA approval action, official labeling, the Federal Register, or another controlling primary source, not a seller, social post, or search snippet.
Federal regulation distinguishes scientific exchange from promotion: it does not restrict full exchange of scientific information, but it does restrict representing an investigational drug as safe or effective in a promotional context and precludes commercialization before approval.
Source records
Snapshot date: 2026-08-09. Records: FDA status statement for unapproved GLP-1 drugs; FDA warning letter addressing compounded retatrutide; 21 CFR 312.7, Promotion of investigational drugs; ClinicalTrials.gov pre-approval expanded-access record NCT07629401; ClinicalTrials.gov record NCT05929066.
Frequently asked questions
What is established about federal Federal Compounding Status Record?
Public sources document study designs, enrolled populations, prespecified endpoints, and regulatory status. They do not establish an FDA-approved indication, public-use instruction, or conclusion beyond those records.
Does this research mean retatrutide is approved or publicly offered?
No. Retatrutide remains investigational, is not available through ordinary commercial prescription or retail sale, cannot be used in compounding under federal law, and is not offered by HealthRX.com.
How can readers verify this review?
Use the linked FDA, eCFR, PubMed, and ClinicalTrials.gov records. Check the source date, study status, population, endpoint definitions, sponsor, and whether results have been peer reviewed.
References
- U.S. Food and Drug Administration. FDA status statement for unapproved GLP-1 drugs. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- U.S. Food and Drug Administration. FDA warning letter addressing compounded retatrutide. 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/asn-labs-09092025
- Electronic Code of Federal Regulations. 21 CFR 312.7, Promotion of investigational drugs. 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.7
- ClinicalTrials.gov. Pre-approval expanded-access registry record. 2026. https://clinicaltrials.gov/study/NCT07629401
- ClinicalTrials.gov. TRIUMPH-1 registry record. 2026. https://clinicaltrials.gov/study/NCT05929066